Development of Modified Citrus Pectin or MCP:
Pectins from white plants have an established role in the GI tract to enhance digestive and immune health. However the main obstacle that prevents them from producing benefits throughout the body is their bio availability. The long soluble fibers of regular pectin are too large to be easily absorbed into circulation. The development of MCP solved this issue. It was developed from regular citrus pectin by a modification process involving high pH and temperature that reduced the size and branching of the molecules. With this modification, MCP was easily absorbed into the system and displayed numerous therapeutic effects.
Modified Citrus Pectin and Cancer:
Research has revealed that MCP or Modified Citrus Pectin is a powerful anti cancer agent. According to a study, MCP enhanced the effects of two anti cancer formulas, one for breast cancer and the other for prostate cancer. The combination of MCP and the formula displayed reduction in aggressiveness of cancer cells and repressed metastasis in human breast and prostate cancer cells. The breast cancer formula talked about here had already been shown to reduce breast cancer cells adhesion by 21% and the prostate cancer formula was effective in the same task by 9%, however when combined with MCP, the reduction went up to 40% in both cases which is a huge response.
Urokinase plasminogen activator or uPA is a protein marker for cancers. High levels of this marker have been shown to promote cancer cell adhesion and invasion. MCP’s role in the above mentioned formulas is to suppress uPA. A number of studied have revealed that MCP acts as a gelactin-3 blocker. Gelactin-3 is a signaling protein that is related to the aggressiveness of cancer cells, aggregation, angiogenesis and metastasis. MCP has also displayed excellent response in significantly increasing activity against human leukemia cells. In addition to its effectiveness when combined with botanical formulas, it has been shown to work harmoniously with chemotherapeutic agents such as doxorubicin to allow lower dosages and lesser side effects.
Modified Citrus Pectin and chelation:
Heavy metals toxicity is a big concern with health authorities and associations worldwide. With the increasing number of cases of exposure to heavy metal toxicity, there is an urgent need of a chelating agent to overcome the challenge.
MCP has displayed wide usage other than just fighting cancer. It has found many applications in reducing health problems caused by toxic heavy metals such as lead though a therapy called heavy metal detoxification therapy. In chelation therapy, a substance is used to unite molecules of heavy toxic metals and hold them together so that they can be removed together from the system such as a human body. chelation thearpy is widely used in treating mercury and lead poisoning by getting rid of toxic metals.
A clinical study was performed to assess oral use of MCP for Chelation and determine if it lowered blood toxicity in children aged 5-12 years. Children with a blood serum level of 20 mcg/dL and who had not received any medication for detoxification were administered 15g of MCP divided into three doses per day. Blood serum and 24 hr urine excretion were analyzed every week. The results were a dramatic decrease in the blood serum levels of lead and an increase in 24 hr urine collection.
There is a huge need of a safe and gentle chelating agent especially for people who have high exposure to toxic metals in their work environment. The dramatic results of the study mentioned above and absolutely no side effects of MCP have made MCP emerge as such an agent. Further studies have confirmed the findings of the pilot study to establish MCP as a chelating agent.
Modified Citrus Pectin and Metastasis:
Metastasis can be defined as the spread of cancer to distant tissues and organs from the primary site of occurrence of tumor. It is metastasis that makes cancer so deadly and is the biggest challenge that cancer poses. MCP has emerged as one of the most effective anti metastasis drugs. Ever since the first report of MCP acting as melanoma and prostate carcinoma inhibitor appeared, this compound has been the center of attention of the cancer research community. MCP has shown to be effective against a number of cancers viz. colon carcinoma, melanoma, multiple myeloma etc. The main action of MCP in prohibiting metastatic spread of various malignancies stems out from its ability to antagonize galectin-3, a beta-galactoside binding protein.